Morgan Birch, DO
Family Medicine · Hazard, KYNPI 1982962874
Payments from drug & device makers
What this record shows
24 manufacturers reported payments, led by Alkermes, Inc. at 56.2% of the total. Reporting peaked in 2021 at $2,400 and has fallen 92.0% since, to $191 in 2025.
Across 100 payments — averaging $47.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$3K
- AbbVie$896
- Seqirus USA Inc$154
- Indivior Inc.$134
- Lilly USA, LLC$103
- Merck$102
- plus $707 from 18 others
What the payments were for
- Speaking & faculty fees$2,64055%
- Food & beverage$2,14045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 8 | $2,685 |
| AbbVie | 33 | $896 |
| Seqirus USA Inc | 1 | $154 |
| Indivior Inc. | 6 | $134 |
| Lilly USA, LLC | 7 | $103 |
| Merck | 6 | $102 |
| Covidien LP | 2 | $93 |
| Medtronic | 5 | $91 |
| Amgen | 4 | $75 |
| AstraZeneca | 4 | $58 |
| Novo Nordisk | 4 | $56 |
| Johnson & Johnson | 3 | $52 |
| Grifols USA, LLC | 2 | $41 |
| Biogen | 2 | $36 |
| Gilead | 2 | $31 |
| Mylan Specialty L.p. | 2 | $30 |
| Pfizer | 2 | $26 |
| Shield Therapeutics Inc | 1 | $25 |
| Bayer | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Baxter Healthcare | 1 | $13 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,780 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $97,636 |
| MounjaroTirzepatide | 48 | $60,298 |
| OzempicSemaglutide | 34 | $41,384 |
| JardianceEmpagliflozin | 39 | $40,656 |
| JanuviaSitagliptin Phosphate | 41 | $39,912 |
| VraylarCariprazine Hcl | 21 | $37,824 |
| TrulicityDulaglutide | 27 | $36,812 |
| LinzessLinaclotide | 36 | $30,827 |
| FarxigaDapagliflozin Propanediol | 27 | $28,162 |
| SublocadeBuprenorphine | 13 | $26,623 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $17,962 |
| Repatha SureclickEvolocumab | 26 | $15,571 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $14,206 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $13,880 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 69 | $13,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $26 | $100,765111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $103 | $97,11075 claims |
| AbbVieVraylar, Linzess | $896 | $68,65157 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $58 | $49,77857 claims |
| Novo NordiskOzempic | $56 | $41,38434 claims |
| MerckJanuvia | $102 | $39,91241 claims |
| GSKAnoro Ellipta, Shingrix | $13 | $27,80789 claims |
| Indivior Inc.Sublocade | $134 | $26,62313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Hazard
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
- Derek JonesAshland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.